Jeremy N. Rich

This study identifies metabolic partnerships between medulloblastoma and macrophages that drive leptomeningeal metastases and suggests targeting the CXCL12-SCARB1-cholesterol axis as a therapeutic strategy.

The paper identifies ependymomas as originating from the pre-neural crest/roof plate lineage using single-cell transcriptomics and lineage tracing.

This study identifies that rAAV toxicity in dividing cells results from depletion of PARP1 and other DNA damage response proteins, leading to replication stress and cell death.

This paper introduces a gel-top culture model that replicates mesenchymal features of glioblastoma cells and identifies CK2 as a potential therapeutic target.

This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.

This study develops a dCasRx-based platform to edit m6A RNA modifications and demonstrates its use in studying m6A-binding protein functions.

This study identifies sex differences in glioblastoma driven by Brd4-bound enhancers, showing opposing responses to BET inhibitors in male and female tumor cells.